As the era of blockbuster obesity drugs strains against the limits of affordability and access, Dr Reddy's Laboratories has secured a pivotal regulatory recommendation in India to manufacture generic semaglutide — the weight-loss compound that has reshaped modern medicine. With Novo Nordisk's patent set to expire in March 2026, the Hyderabad-based firm is preparing to enter a global market still largely out of reach for millions of patients, betting that the democratization of these medicines will create opportunity as vast as the unmet need itself.
Dr Reddy's cleared to launch generic semaglutide after Novo Nordisk patent expires
The market will grow, and players with control over the value chain will benefit
Mark
Why does it matter that Dr Reddy's got this approval now, months before the patent actually expires?
Mimi
Because regulatory approval is the bottleneck, not the patent expiry itself. Once March 2026 arrives, Dr Reddy's can manufacture immediately—they won't be waiting in a queue. That head start could mean weeks or months of market dominance before competitors catch up.
Mark
But Eli Lilly's tirzepatide is already winning in India. Why would patients switch to a generic semaglutide?
Mimi
Price, mostly. Tirzepatide may be better for some patients, but if a generic semaglutide costs half as much, many doctors and patients will choose it. The market is also big enough for both—most people who need these drugs still can't access them at all.
Mark
The company said it's not partnering with Lilly. Does that mean they're conceding the tirzepatide market?
Mimi
Not conceding—just choosing their battle. Lilly owns tirzepatide and will defend it fiercely. Semaglutide is a clearer path: the patent expires, generics flood in, and Dr Reddy's can compete on manufacturing scale and cost. It's a different game.
Mark
What about the 87 countries they mentioned for 2026?
Mimi
That's the real bet. India is just one market. If Dr Reddy's can launch generics across dozens of countries simultaneously, they become a global supplier for a drug that billions of people will eventually need. That's not a quarterly win—that's a decade-long revenue stream.
Mark
Will the price actually drop when generics arrive?
Mimi
It always does. The question is how much. Semaglutide is complex to manufacture, so generic prices won't plummet like they do for simple pills. But they'll fall enough to open access for millions more patients who couldn't afford the brand-name version.
The Pulse
- Semaglutide has become one of the world's most coveted drugs, yet in India it trails rival tirzepatide badly — Rs 28 crore against Rs 112 crore — revealing that price and access, not just efficacy, determine who wins these markets.
- Dr Reddy's regulatory clearance from an expert committee is a meaningful first step, but final approval from the Drug Controller General of India still stands between the company and its launch window.
- The company is racing against a crowded field: multiple manufacturers globally are preparing to flood the generic semaglutide market the moment patent protections lapse, making early-mover positioning critical.
- Dr Reddy's has staked out an ambitious response — planned launches across 87 countries in 2026 — framing semaglutide not as a single product but as a long-term growth engine to offset margin pressure in its US generics business.
- Executives have ruled out a tirzepatide partnership with Eli Lilly and declined to name a price, but their language — 'competitive' — signals an intent to undercut the branded market and expand the overall patient base rather than simply divide existing demand.
As the era of blockbuster obesity drugs strains against the limits of affordability and access, Dr Reddy's Laboratories has secured a pivotal regulatory recommendation in India to manufacture generic semaglutide — the weight-loss compound that has reshaped modern medicine. With Novo Nordisk's patent set to expire in March 2026, the Hyderabad-based firm is preparing to enter a global market still largely out of reach for millions of patients, betting that the democratization of these medicines will create opportunity as vast as the unmet need itself.
Dr Reddy's Laboratories has cleared a significant regulatory milestone: an expert committee under India's Central Drugs Standard Control Organization has recommended approval for the Hyderabad-based company to manufacture and market generic semaglutide. Final sign-off from the Drug Controller General of India is still pending, but the company is already oriented toward a March 2026 launch — the moment Novo Nordisk's patent protection on the blockbuster weight-loss and diabetes drug expires.
The Indian market offers a revealing preview of the competitive dynamics ahead. Novo Nordisk's branded semaglutide, sold as Wegovy, has generated only Rs 28 crore in four months since its June launch, while Eli Lilly's tirzepatide — marketed as Mounjaro — accumulated Rs 112 crore in its first six months. The gap points to the outsized role that pricing, physician preference, and availability play in shaping adoption, even for drugs with strong clinical profiles.
Dr Reddy's is betting that generic entry rewrites those dynamics. The company has announced plans to launch semaglutide generics across 87 countries in 2026, and its chief executive for branded markets described the obesity and diabetes space as vastly underserved — a market where millions of eligible patients remain priced out entirely. Generic competition, the argument goes, won't simply redistribute existing demand; it will expand the pool of patients who can access treatment at all.
The company has not disclosed pricing but has signaled it will be competitive, and has explicitly ruled out any partnership with Eli Lilly on tirzepatide, choosing to concentrate its resources on semaglutide. That focus comes against a backdrop of financial pressure: while Dr Reddy's posted a 9.8 percent revenue increase and a 14 percent rise in profit after tax in its most recent quarter, margins have been squeezed by US generics price erosion and weaker Lenalidomide sales. Semaglutide represents a high-volume opportunity to offset those headwinds.
Dr Reddy's will not be alone in this race — the generic semaglutide market will attract multiple entrants simultaneously. But its early regulatory clearance and the scale of its stated global ambitions suggest the company is positioning itself to be among the first to move, and in a category this large and this hungry for affordable options, that timing may prove decisive.
Dr Reddy's Laboratories, the Hyderabad-based pharmaceutical giant, has cleared a significant regulatory hurdle. An expert committee under India's Central Drugs Standard Control Organization has recommended approval for the company to manufacture and market generic semaglutide—the blockbuster weight loss and diabetes drug that has reshaped the obesity treatment landscape. The company is now waiting for final sign-off from the Drug Controller General of India, after which it plans to launch as soon as Novo Nordisk's patent protection expires in March 2026.
The timing matters. Semaglutide, sold by Novo Nordisk under the brand name Wegovy, has become one of the most sought-after medications in the world, commanding premium prices and generating intense demand among patients and physicians. In India, however, the drug has faced unexpected competition. Eli Lilly's tirzepatide, marketed as Mounjaro, has captured the market more aggressively—racking up Rs 112 crore in sales over six months of launch, compared to Wegovy's Rs 28 crore across four months since June. The gap suggests that price, availability, or physician preference has favored Lilly's offering, at least in the Indian market so far.
Dr Reddy's is betting that generic entry will change the equation. The company has already signaled its global ambitions: it plans to launch semaglutide generics across 87 countries in 2026, positioning the drug as a future growth engine. MV Ramana, the company's chief executive for branded markets in India and emerging regions, acknowledged the competitive landscape but expressed confidence in the underlying demand. He noted that the market for obesity and diabetes management remains vastly underserved—millions of patients who could benefit from these drugs still lack access, either because of cost or availability. Once patents expire and generic versions flood the market, he suggested, the overall pie will expand, and companies with control over manufacturing and distribution will capture meaningful share.
The company has not disclosed pricing for its generic version, but executives made clear it will be competitive. That language carries weight in a market where Mounjaro has already set expectations and where multiple manufacturers are preparing to enter simultaneously. Dr Reddy's also ruled out any partnership with Eli Lilly for tirzepatide, signaling it will focus its energy on semaglutide rather than chase Lilly's lead product.
The broader context: Dr Reddy's reported strong financial results for the second quarter, with consolidated revenues rising 9.8 percent year-on-year to Rs 8,805 crore and profit after tax climbing 14 percent to Rs 1,437 crore. Yet margins contracted, squeezed by price erosion in the US generics business and lower sales of Lenalidomide. The semaglutide opportunity represents a chance to offset those headwinds with a high-volume, high-demand product in a category that is still in its infancy in most markets. The company's global regulatory conversations are already underway, with the goal of launching in each market as soon as patent protection lapses.
What happens next depends partly on how quickly other manufacturers move. The generic semaglutide market will not belong to Dr Reddy's alone. But the company's early regulatory clearance and stated ambition to launch across dozens of countries suggest it is positioning itself to be among the first movers—and in a market this large and this hungry, that timing could prove decisive.
Notable Quotes
Our aspiration is to launch the product as soon as the patent expires— MV Ramana, CEO of branded markets, Dr Reddy's Laboratories
We expect a significant amount of unmet need both from the point of diabetes and the ability to manage obesity so this market will grow— MV Ramana, Dr Reddy's Laboratories
Want the full story?
Read the original at The Economic Times ↗
Health & Medicine